Neurocrine Biosciences | NBIX - Cash And Equivalent


Neurocrine Biosciences reported $266.5M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Exelixis USD 226.15M 256.34M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Prothena USD 329.46M 21.93M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Repligen USD 582.65M 16.63M Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026